ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 171 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2022. The put-call ratio across all filers is 0.24 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1 | -97.5% | 628 | -97.5% | 0.00% | – |
| Q1 2023 | $40 | -85.9% | 25,028 | -44.8% | 0.00% | – |
| Q4 2022 | $283 | -99.9% | 45,381 | +0.0% | 0.00% | – |
| Q3 2022 | $304,000 | +55.9% | 45,379 | +48.3% | 0.00% | – |
| Q2 2022 | $195,000 | +58.5% | 30,590 | +15.7% | 0.00% | – |
| Q1 2022 | $123,000 | +11.8% | 26,429 | +20.5% | 0.00% | – |
| Q4 2021 | $110,000 | -81.6% | 21,929 | -55.8% | 0.00% | -100.0% |
| Q3 2021 | $597,000 | -43.0% | 49,575 | +0.1% | 0.00% | 0.0% |
| Q2 2021 | $1,048,000 | -38.0% | 49,543 | -17.8% | 0.00% | -50.0% |
| Q1 2021 | $1,691,000 | +7.9% | 60,271 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,567,000 | -38.1% | 60,271 | -11.5% | 0.00% | -33.3% |
| Q3 2020 | $2,530,000 | -11.3% | 68,068 | +22.5% | 0.00% | -25.0% |
| Q2 2020 | $2,851,000 | +83.0% | 55,568 | +12.4% | 0.00% | +100.0% |
| Q1 2020 | $1,558,000 | -52.6% | 49,418 | -10.3% | 0.00% | -50.0% |
| Q4 2019 | $3,285,000 | +135.1% | 55,097 | +44.6% | 0.00% | +100.0% |
| Q3 2019 | $1,397,000 | +17.3% | 38,100 | +48.8% | 0.00% | +100.0% |
| Q2 2019 | $1,191,000 | +27.9% | 25,600 | +10.3% | 0.00% | 0.0% |
| Q1 2019 | $931,000 | -33.4% | 23,200 | -23.7% | 0.00% | -50.0% |
| Q4 2018 | $1,398,000 | -15.3% | 30,400 | -18.2% | 0.00% | 0.0% |
| Q3 2018 | $1,650,000 | +13.2% | 37,177 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,457,000 | -32.0% | 37,177 | +25.5% | 0.00% | -33.3% |
| Q1 2018 | $2,143,000 | -53.7% | 29,627 | -57.8% | 0.00% | -50.0% |
| Q4 2017 | $4,627,000 | +480.6% | 70,272 | +342.0% | 0.01% | +500.0% |
| Q3 2017 | $797,000 | +8.3% | 15,900 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $736,000 | +31.2% | 15,900 | -0.0% | 0.00% | 0.0% |
| Q1 2017 | $561,000 | +242.1% | 15,901 | +21.4% | 0.00% | – |
| Q4 2016 | $164,000 | -9.4% | 13,100 | 0.0% | 0.00% | – |
| Q3 2016 | $181,000 | +40.3% | 13,100 | 0.0% | 0.00% | – |
| Q2 2016 | $129,000 | -41.9% | 13,100 | 0.0% | 0.00% | – |
| Q1 2016 | $222,000 | -24.0% | 13,100 | 0.0% | 0.00% | – |
| Q4 2015 | $292,000 | -5.5% | 13,100 | 0.0% | 0.00% | – |
| Q3 2015 | $309,000 | -75.1% | 13,100 | -13.8% | 0.00% | -100.0% |
| Q2 2015 | $1,242,000 | +251.8% | 15,193 | +298.2% | 0.00% | +100.0% |
| Q1 2015 | $353,000 | – | 3,815 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |